154 related articles for article (PubMed ID: 9258753)
1. Cortical remodeling following suppression of endogenous estrogen with analogs of gonadotrophin releasing hormone.
Bell KL; Loveridge N; Lindsay PC; Lunt M; Garrahan N; Compston JE; Reeve J
J Bone Miner Res; 1997 Aug; 12(8):1231-40. PubMed ID: 9258753
[TBL] [Abstract][Full Text] [Related]
2. The effects of gonadotrophin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis.
Compston JE; Yamaguchi K; Croucher PI; Garrahan NJ; Lindsay PC; Shaw RW
Bone; 1995 Feb; 16(2):261-7. PubMed ID: 7756056
[TBL] [Abstract][Full Text] [Related]
3. Effect of estrogen suppression on the mineralization density of iliac crest biopsies in young women as assessed by backscattered electron imaging.
Boyde A; Compston JE; Reeve J; Bell KL; Noble BS; Jones SJ; Loveridge N
Bone; 1998 Mar; 22(3):241-50. PubMed ID: 9514216
[TBL] [Abstract][Full Text] [Related]
4. Changes in bone turnover during tibolone treatment.
Riera-Espinoza G; Ramos J; Carvajal R; Belzares E; Stanbury G; Farías R; Valderrama I; Alvarez K; Riera-González G
Maturitas; 2004 Feb; 47(2):83-90. PubMed ID: 14757266
[TBL] [Abstract][Full Text] [Related]
5. Intracapsular hip fracture: increased cortical remodeling in the thinned and porous anterior region of the femoral neck.
Bell KL; Loveridge N; Power J; Rushton N; Reeve J
Osteoporos Int; 1999; 10(3):248-57. PubMed ID: 10525718
[TBL] [Abstract][Full Text] [Related]
6. Biochemical markers as predictors of bone mineral density changes after GnRH agonist treatment.
Borderie D; Cherruau B; Dougados M; Ekindjian OG; Roux C
Calcif Tissue Int; 1998 Jan; 62(1):21-5. PubMed ID: 9405728
[TBL] [Abstract][Full Text] [Related]
7. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability.
Hannon R; Blumsohn A; Naylor K; Eastell R
J Bone Miner Res; 1998 Jul; 13(7):1124-33. PubMed ID: 9661076
[TBL] [Abstract][Full Text] [Related]
8. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84.
Recker RR; Bare SP; Smith SY; Varela A; Miller MA; Morris SA; Fox J
Bone; 2009 Jan; 44(1):113-9. PubMed ID: 18983947
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety investigation of Kuntai capsule for the add-back therapy of gonadotropin releasing hormone agonist administration to endometriosis patients: a randomized, double-blind, blank- and tibolone-controlled study.
Chen JM; Gao HY; Ding Y; Yuan X; Wang Q; Li Q; Jiang GH
Chin Med J (Engl); 2015 Feb; 128(4):427-32. PubMed ID: 25673440
[TBL] [Abstract][Full Text] [Related]
10. A histomorphometric study of cortical bone of the iliac crest in patients treated with glucocorticoids.
Vedi S; Elkin SL; Compston JE
Calcif Tissue Int; 2005 Aug; 77(2):79-83. PubMed ID: 16086108
[TBL] [Abstract][Full Text] [Related]
11. The effects of long-term hormone replacement therapy on bone remodeling in postmenopausal women.
Vedi S; Compston JE
Bone; 1996 Nov; 19(5):535-9. PubMed ID: 8922654
[TBL] [Abstract][Full Text] [Related]
12. Alendronate rescued osteoporotic phenotype in a model of glucocorticoid-induced osteoporosis in adult zebrafish scale.
Pasqualetti S; Congiu T; Banfi G; Mariotti M
Int J Exp Pathol; 2015 Feb; 96(1):11-20. PubMed ID: 25603732
[TBL] [Abstract][Full Text] [Related]
13. Estrogen and bone metabolism.
Väänänen HK; Härkönen PL
Maturitas; 1996 May; 23 Suppl():S65-9. PubMed ID: 8865143
[TBL] [Abstract][Full Text] [Related]
14. The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl).
Lindsay PC; Shaw RW; Bennink HJ; Kicovic P
Fertil Steril; 1996 Feb; 65(2):342-8. PubMed ID: 8566259
[TBL] [Abstract][Full Text] [Related]
15. Fluctuation of mineral apposition rate at individual bone-remodeling sites in human iliac cancellous bone: independent correlations with osteoid width and osteoblastic alkaline phosphatase activity.
Bradbeer JN; Lindsay PC; Reeve J
J Bone Miner Res; 1994 Nov; 9(11):1679-86. PubMed ID: 7863818
[TBL] [Abstract][Full Text] [Related]
16. Effect of estrogen on the activity and growth of human osteoclasts in vitro.
Chen FP; Wang KC; Huang JD
Taiwan J Obstet Gynecol; 2009 Dec; 48(4):350-5. PubMed ID: 20045755
[TBL] [Abstract][Full Text] [Related]
17. [A meta-analysis of preventing bone mineral loss in patients with endometriosis treated by gonadotrophin-releasing hormone analogues with add-back therapy].
Niu ZR; Yue XJ; Kong QY; Wang YF; Yao YQ
Zhonghua Fu Chan Ke Za Zhi; 2013 May; 48(5):338-43. PubMed ID: 24016475
[TBL] [Abstract][Full Text] [Related]
18. Gonadotrophin receptor hormone analogues in combination with add-back therapy: an update.
McLaren JS; Morris E; Rymer J
Menopause Int; 2012 Jun; 18(2):68-72. PubMed ID: 22611225
[TBL] [Abstract][Full Text] [Related]
19. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis.
Dalle Carbonare L; Arlot ME; Chavassieux PM; Roux JP; Portero NR; Meunier PJ
J Bone Miner Res; 2001 Jan; 16(1):97-103. PubMed ID: 11149495
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms by which high-dose estrogen therapy produces anabolic skeletal effects in postmenopausal women: role of locally produced growth factors.
Bord S; Beavan S; Ireland D; Horner A; Compston JE
Bone; 2001 Sep; 29(3):216-22. PubMed ID: 11557364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
